All News
CXCR3 and Restricted T Cells in Psoriatic Arthritis Inflammation
Research from Oxford University suggests a potential pathogenic role for the chemokine CXCR3 and clonally restricted CD8+ T cells in the pathogenesis of psoriatic arthritis (PsA) based studies of PsA synovial fluid samples obtained by arthrocentesis from 11 patients with large-joint oligo Ps
Read Article
DMARDs for Early Rheumatoid Arthritis Have Cardiovascular Benefits
Patients with RA have up to a three-fold increased risk of mortality versus the general population, largely due to an increased incidence of premature CVD, such as atherosclerosis and heart failure.
Read Article
RheumNow Podcast – Lupus Delights (9.18.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
Read Article
COVID-19 Risks in Pregnant Women
There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports
Read Article
Methotrexate-Pegloticase Combination in Refractory Gout - MIRROR Study
The MIRROR study, an open-label pilot trial in refractory, uncontrolled gout patients, showed that pegloticase given in combination with methotrexate was safe and effective and maintained responses for 6 months after initiation.
Read Article
Belimumab Effective in Lupus Nephritis
Dr. Rich Furie has lead a group of investIgators in reporting the significant efficacy of intravenous belimumab when added to standard of care induction therapy in patients with active lupus nephritis. This phase 3, 2-year study included 448 systemic lupus erythematosus patients with biopsy proven lupus nephritis (class III or IV +/- V) patients who required induction therapy and have a UPCR ≥1 g/g.
Read Article
Has the Risk of Hip Fracture Changed over Time?
Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking).
Read Article
NSAIDs Shows No Advantage over CBT in Knee Osteoarthritis
JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
HCPLive MDMagazine ( View Tweet)
Bella Mehta bella_mehta ( View Tweet)
HCPLive MDMagazine ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)